8-K: Avalon GloboCare Expands KetoAir, Launches Health Programs

Avalon GloboCare announced Q3 2025 progress for its KetoAir breathalyzer, including a first-responder health program and international expansion into the UK.

Summary

• Launched the Nevada POOL/PACT Holistic Health Reset program in August 2025 for 50 first responders, utilizing KetoAir for continuous daily monitoring of metabolic changes.
• Began offering the FDA-registered KetoAir breathalyzer device for purchase in the United Kingdom via www.KetoAir.uk on September 1, 2025, marking the first international expansion.
• Showcased KetoAir at the London Health Optimization Summit on September 13th and 14th, 2025, demonstrating its integration into broader wellness programs.
• Mid-program data from the Nevada first responder initiative in October 2025 indicated individual improvements in metabolic health.
• KetoAir is a handheld breathalyzer designed for ketogenic health management, measuring breath acetone concentration (BrAce), and is compatible with Apple and Android devices.
• The company continues to focus on advancing its intellectual property portfolio and owns and operates commercial real estate.
• Avalon has filed a Registration Statement on Form S-4 with the SEC regarding a proposed merger with YOOV Group Holding Limited.

Sentiment

Score: 7

Explanation: The filing reports positive operational progress, including market expansion and program launches, indicating growth and execution. However, it lacks specific financial metrics and highlights general forward-looking statement risks. The mention of a proposed merger adds a layer of strategic activity.

Positives

• Successful launch of the Nevada POOL/PACT Holistic Health Reset program with 50 first responders, demonstrating real-world application and positive mid-program results for metabolic health.
• Achieved first international market expansion for KetoAir with its launch in the United Kingdom on September 1, 2025, opening a new significant market.
• KetoAir was showcased at the London Health Optimization Summit, increasing visibility and demonstrating integration into broader wellness programs.
• KetoAir is an FDA-registered Class I medical device (registration number: 3026284320), lending credibility and regulatory approval.
• The company is actively advancing its intellectual property portfolio.

Risks

• Forward-looking statements involve risks and uncertainties, and actual results may differ materially from expectations.
• General industry and market conditions, growth rates, economic conditions, and governmental and public policy changes can impact future performance.
• Risks associated with the ability to enter into a definitive agreement for the proposed merger with YOOV Group Holding Limited.
• Risks related to the commercialization, distribution, and sales of its products and the products' ability to compete with other similar products.

Future Outlook

The company expects continued momentum for KetoAir as it expands into new markets and introduces solutions to meet the growing global demand for metabolic-health tools. It also plans to develop additional diagnostic uses of the breathalyzer technology and advance its intellectual property portfolio. The proposed merger with YOOV Group Holding Limited is ongoing, with a Registration Statement on Form S-4 filed with the SEC.

Management Comments

• "Our Q3 achievements reflect momentum for KetoAir as we expand into new markets and introduce solutions that meet the growing global demand for metabolic-health tools." Meng Li, Interim Chief Executive Officer and Chief Operating Officer of Avalon.

Industry Context

The announcement aligns with the growing global demand for metabolic health tools and personalized wellness solutions, particularly in the areas of ketogenic diets, weight loss, and athletic performance. The expansion into the UK market positions Avalon to tap into a broader international health and wellness technology market. The focus on first responders also highlights a niche application within corporate wellness programs, a growing segment of the health industry.

Comparison to Industry Standards

• The KetoAir device, as an FDA-registered Class I medical device, meets regulatory standards for safety and effectiveness in the U.S. market, comparable to other regulated medical devices in the diagnostic space.
• The expansion into the UK market positions Avalon to compete with other health tech companies offering metabolic monitoring solutions in Europe, such as those providing continuous glucose monitors or other breath analysis devices.
• The "Holistic Health Reset Program" for first responders is an example of a corporate wellness initiative, a growing trend in employee benefits, comparable to programs offered by companies like Virgin Pulse or Welltok, though specifically focused on metabolic health and utilizing a proprietary device.

Stakeholder Impact

• Shareholders: Potential positive impact from market expansion, product adoption, and strategic merger activities, but also subject to risks associated with forward-looking statements and merger completion.
• Customers (KetoAir users): Benefit from expanded availability (UK launch) and integration into structured wellness programs (first responders).
• Employees: Potential for growth and new opportunities due to company expansion and product development.
• First Responders (Nevada program): Direct benefit from the "Holistic Health Reset program" aimed at improving metabolic, physical, and behavioral health.

Next Steps

• Continue expanding KetoAir into new markets.
• Introduce further solutions to meet global demand for metabolic-health tools.
• Develop additional diagnostic uses of the breathalyzer technology.
• Advance the intellectual property portfolio through existing patent applications.
• Proceed with the proposed merger with YOOV Group Holding Limited, including the SEC review of the Registration Statement on Form S-4.

Key Dates

Recommendation

The filing indicates positive operational momentum with market expansion and product adoption, which are good signs for future growth. However, the absence of specific financial metrics makes it difficult to assess the immediate impact on profitability or revenue. The ongoing merger process introduces both potential upside and execution risk. For a seasoned investor, these developments suggest the company is executing its strategy, but without financial performance data, a "hold" position is prudent to observe the financial impact of these initiatives and the merger's progress.

Keywords

KetoAir, breathalyzer, metabolic health, ketosis, wellness program, FDA-registered, international expansion, UK market, Avalon GloboCare, ALBT, diagnostic products, YOOV Group Holding Limited, merger